These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20331453)

  • 1. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
    Singh AV; Palladino MA; Lloyd GK; Potts BC; Chauhan D; Anderson KC
    Br J Haematol; 2010 May; 149(4):550-9. PubMed ID: 20331453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
    Chauhan D; Hideshima T; Anderson KC
    Br J Cancer; 2006 Oct; 95(8):961-5. PubMed ID: 17047643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
    Chauhan D; Singh AV; Ciccarelli B; Richardson PG; Palladino MA; Anderson KC
    Blood; 2010 Jan; 115(4):834-45. PubMed ID: 19965674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
    Chauhan D; Singh A; Brahmandam M; Podar K; Hideshima T; Richardson P; Munshi N; Palladino MA; Anderson KC
    Blood; 2008 Feb; 111(3):1654-64. PubMed ID: 18006697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
    Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
    Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
    Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
    Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
    Ruiz S; Krupnik Y; Keating M; Chandra J; Palladino M; McConkey D
    Mol Cancer Ther; 2006 Jul; 5(7):1836-43. PubMed ID: 16891470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
    Levin N; Spencer A; Harrison SJ; Chauhan D; Burrows FJ; Anderson KC; Reich SD; Richardson PG; Trikha M
    Br J Haematol; 2016 Sep; 174(5):711-20. PubMed ID: 27161872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
    Raninga PV; Lee A; Sinha D; Dong LF; Datta KK; Lu X; Kalita-de Croft P; Dutt M; Hill M; Pouliot N; Gowda H; Kalimutho M; Neuzil J; Khanna KK
    Theranostics; 2020; 10(12):5259-5275. PubMed ID: 32373211
    [No Abstract]   [Full Text] [Related]  

  • 12. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.
    Miller CP; Ban K; Dujka ME; McConkey DJ; Munsell M; Palladino M; Chandra J
    Blood; 2007 Jul; 110(1):267-77. PubMed ID: 17356134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
    Cusack JC; Liu R; Xia L; Chao TH; Pien C; Niu W; Palombella VJ; Neuteboom ST; Palladino MA
    Clin Cancer Res; 2006 Nov; 12(22):6758-64. PubMed ID: 17121896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
    Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J
    Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marizomib, a potent second generation proteasome inhibitor from natural origin.
    Ma L; Diao A
    Anticancer Agents Med Chem; 2015; 15(3):298-306. PubMed ID: 25403165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
    Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.
    Singh AV; Bandi M; Aujay MA; Kirk CJ; Hark DE; Raje N; Chauhan D; Anderson KC
    Br J Haematol; 2011 Jan; 152(2):155-63. PubMed ID: 21114484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NPI-0052 and γ-radiation induce a synergistic apoptotic effect in medulloblastoma.
    Frisira E; Rashid F; Varma SN; Badodi S; Benjamin-Ombo VA; Michod D; Niklison-Chirou MV
    Cell Death Dis; 2019 Oct; 10(11):785. PubMed ID: 31619667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.